Interactions between human mesenchymal stem cells and natural killer cells

Stem Cells

Volumn 24, Issue 1, 2006, Pages 74-85

  Sotiropoulou, Panagiota A ^a   Perez, Sonia A ^a   Gritzapis, Angelos D ^a   Baxevanis, Constantin N ^a   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Cytotoxicity; Immunosuppression; Mesenchymal stem cells; Natural killer cells

Indexed keywords

HLA ANTIGEN CLASS 1; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1;

ALLOIMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NATURAL KILLER T CELL; PHENOTYPE; T LYMPHOCYTE ACTIVATION; TISSUE ENGINEERING;

ADULT; CELL COMMUNICATION; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; MESENCHYMAL STEM CELLS; PHENOTYPE;

EID: 33645508766     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2004-0359     Document Type: Article

References (48)

1. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
2. Minguell JJ, Erices A, Congel P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001;226:507-520.
3. Barry L, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-584.
4. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000;109:235-242.
5. Zuk PA, Zhii M, Mizuno H. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-228.
6. Chapel A, Bertho JM, Bensidhoum M et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003;5: 1028-1038.
7. Devine SM, Cobbs C, Jennings M et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001.
8. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
9. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-3729.
10. Meisel R, Ziberl A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2.3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621.
11. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004;13:263-271.
12. Han Q, Deng W, Li C. Allogeneic adult stem cells establish long-term residence in recipient tissues and facilitate skin transplantation. Exp Hematol 2003;31:158a.
13. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48.
14. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76: 1208-1213.
15. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;6:485-489.
16. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
17. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
18. Papamichail M, Perez SA, Gritzapis AD et al. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 2004;53:176-186.
19. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
20. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359-394.
21. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-F14.
22. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-2438.
23. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
24. Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705.
25. Deng W, Obrocka M, Fischer I et al. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem Biophys Res Commun 2001;282:148-152.
26. Perez SA, Sotiropoulou PA, Gkika DG et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 2003;101:3444-3450.
27. Carson WE, Giri JG, Lindermann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-1403.
28. bright subset. Blood 2001;97:3146-3151.
29. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844.
30. Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-942.
31. Tangye SG, Cherwinski H, Lanier LL et al. 2B4-mediated activation of human natural killer cells. Mol Immunol 2000;37:493-501.
32. Smyth MJ, Hayakawa Y, Takeda K et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-861.
33. Chiesa S, Tomasello E, Vivier E et al. Coordination of activating and inhibitory signals in natural killer cells. Mol Immunol 2005;42:477-484.
34. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-4520.
35. Lauwerys BR, Garot N, Renauld J-C et al. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 2000;165:1847-1853.
36. Koe FJ. Regulation of adaptive immunity by natural killer cells. Immunol Res 1998;17:303-312.
37. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
38. Naume B, Espevik T. Immunoregulatory effects of cytokines on natural killer cells. Scand J Immunol 1994;40:128-134.
39. Chen WS, Kitson RP, Goldfarb RH. Modulation of human NK cell lines by vascular endothelial growth factor receptor VEGFR-1 (FLT-1). In Vivo 2002;16:439-445.
40. Baxevanis CN, Reclos GJ, Gritzapis AD et al. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993;72:491-501.
41. 2 suppressed IL-15-mediated human NK cell function through down-regulation of common g-chain. J Immunol 2001;166:885-891.
42. Bellone G, Aste-Amezaga M, Trinchieri G et al. Regulation of NK cell functions by TGF-b1. J Immunol 1995;155:1066-1073.
43. Lee J-C, Lee K-M, Kim D-W et al. Elevated TGF-b1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172:7335-7340.
44. Kim R, Emi M, Tanabe K et al. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004;100:2281-2291.
45. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
46. Malygin AM, Meri S, Timonen T. Regulation of natural killer cell activity by transforming growth factor-beta and prostaglandin E2. Scand J Immunol 1993;37:71-76.
47. Frumento G, Rotondo R, Tonetti M et al. Tryptophan-derived catabolites are responsible for inhibition of T and Natural Killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-468.
48. Albertsson PA, Basse PH, Hokland M et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003;24:603-609.